Christine Liow

Christine Liow advises clients on key developments in comparative effectiveness research, the impacts of health technology assessments, evidentiary requirements on patient, provider, and payer needs, and strategies for external public and private engagement.

She also has expertise in patient-centered outcomes research and patient-centered care.

Prior to joining Avalere, Christine served as a research and policy intern in the Centers for Disease Control and Prevention’s Office of Public Health Preparedness and Response and as a healthcare analytic consultant intern at Thomson Reuters.

Christine has an MPH in health policy and management from Emory University and a BS in biology from The College of William and Mary.

Authored Content

Under the Medicare Advantage (MA) Star Ratings Program, plans with 4-stars or more receive the greatest benefit from the Quality Bonus Program (QBP) in the form of higher benchmarks and bonus payments.

Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.

Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.

Two decisions finalized in the CY 2020 Medicare Physician Fee Schedule (MPFS) rule have important implications for vaccine policy and access.

On May 24, Avalere policy experts published a piece on the Health Affairs blog highlighting opportunities to leverage quality measurement tied to payment to drive adult immunization uptake and achieve national population health targets.

New research from Avalere finds that the provision of pneumococcal conjugate vaccines increased immediately after ACIP’s 2014 recommendation to add the vaccine to the routine immunization schedule for older adults.

Join Avalere experts for our analysis of CMS’ 2019 Star Ratings and a look at what’s to come for 2020 on our webinar on November 1, 2018.

Quality measurement in the adult vaccine space has evolved rapidly. Recent advancements continue to propel efforts to drive adult immunization uptake.

Avalere has released a new white paper explaining the current insurance coverage requirements for vaccines and the laws that govern those requirements for the Medicare (Parts B and D), Medicaid, and commercial (group and individual) markets.

A new analysis by Avalere finds that, despite efforts by policymakers to encourage broader vaccination rates, Medicare enrollees have limited access to a set of 10 recommended vaccines without having to pay out-of-pocket (e.g., co-payments).